CP-103

**CP-103** is a CardioPharma fixed-dose cardiovascular polypill in development that combines rosuvastatin, telmisartan, and aspirin. Rosuvastatin competitively inhibits HMG-CoA reductase to reduce cholesterol synthesis; telmisartan selectively blocks angiotensin II type 1 receptors to reduce angiotensin II signaling; and aspirin irreversibly inhibits platelet cyclooxygenase activity to provide antiplatelet activity. CardioPharma lists CP-103 as a pipeline product for cardiovascular disease, without stating a clinical development phase. ([cardiopharma.com](https://www.cardiopharma.com/cardiapill-pipeline/))

Other names

rosuvastatin + telmisartan + aspirinrosuvastatin-telmisartan-ASA